Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer

Authors:

Abstract
In 2020, the American Cancer Society reported the largest 1-year decrease in cancer deaths, in large part because of emerging therapeutic developments that prolong time living with advanced cancer.1 These improvements in survival necessitate evidence on how to improve quality of life (QOL) and symptoms, such as dyspnea, among patients with advanced cancer.

This publication has 34 references indexed in Scilit: